Familial Adenomatous Polyposis Treatment Market
Global Familial Adenomatous Polyposis Treatment Market Size, Share, and Trends Analysis Report, By Type (Icosapent, Eflornithine Hydrochloride, Aspirin, CEQ-508, and Others), and By Application (Clinic, Hospital, and Others) for the Forecast (2022-2028) Update Available - Forecast 2024-2030
The global familial adenomatous polyposis treatment market is anticipated to grow at a significant CAGR of 13.9 % during the forecast period. FAP is a hereditary condition. Emerging drugs such as eRapa is expected to boost the market growth over the forecast. The eRapa (encapsulated rapamycin) is a patented, micro-encapsulated formulation of Rapamycin that protects the active ingredient from rapid, low-pH degradation in the stomach. The eRapa drug product consists of sub-micron rapamycin particles incorporated into poly (methyl methacrylate) polymer. Currently, Emotra Bioscience is conducting the Phase II trial to treat Prevent Progression in FAP Patients, which is expected to propel the growth of the market.
Impact of COVID-19 Pandemic on Global Familial Adenomatous Polyposis Treatment Market
The COVID-19 pandemic had impacted the global adenomatous polyposis industry significantly owning to the lockdown in most of the nations to control the spread of the virus. It affected the overall demand for the drug in the market. It is also believed that it impacts about 50,000 American households. Furthermore, according to the American Society of Clinical Oncology (ASCO), most persons with FAP will have several colon polyps by the age of 35, and around 30% of people with FAP have no family history of the disorder.
Segmental Outlook
The global adenomatous polyposis treatment market is segmented based on type and application. Based on the type, the market is segmented into Icosapent, Eflornithine Hydrochloride, Aspirin, CEQ-508, and others. Based on the application, the market is sub-segmented into the Hospital, Clinics, and others. Among all segments, aspirin is expected to contribute a prominent share in the market over the forecast. Low-dose aspirin safely suppressed the recurrence of colorectal polyps larger than 5·0 mm in patients with FAP. These results suggest an effect of low-dose aspirin for FAP and could be an alternative method for preventing colorectal cancer in FAP, which will drive the growth of the market.
Global Familial Adenomatous Polyposis Treatment Market Share by Application, 2021 (%)
The Hospital Segment Holds the Significant Share in the Global Familial Adenomatous Polyposis Treatment Market
The Hospital segment holds a significant share in the market & is anticipated to grow significantly in the global adenomatous polyposis treatment market over the forecast. According to the National Organization for Rare Disorders (NORD), Familial adenomatous polyposis affects males and females in equal numbers. It occurs in approximately one in 5,000 to 10,000 individuals in the United States and accounts for about 0.5% of all cases of colorectal cancer. One estimate suggests that familial adenomatous polyposis affects 50,000 American families. According to national registries, familial adenomatous polyposis occurs in 2.29-3.2 per 100,000 individuals.
Regional Outlooks
The global adenomatous polyposis treatment market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East & Africa, and Latin America). Among the regions, the Asia Pacific is anticipated as the fastest-growing region. Due to the increasing geriatric population across the countries such as India, China is propelling the growth of the market
Global Familial Adenomatous Polyposis Treatment Market Growth, by Region 2022-2028
The North America Region Expected to Hold Considerable Share in the Global Familial Adenomatous Polyposis Treatment Market
The North America region is expected to hold a considerable share in the adenomatous polyposis treatment market over the forecast. According to the National Organization for Rare Disorders (NORD), FAP affects both men and women equally and affects one in every 5,000 to 10,000 people in the U.S. Furthermore, it accounts for around 0.5 percent of all incidences of colorectal cancer. Furthermore, it is believed that patients with FAP have a one-hundred percent chance of developing colorectal cancer if polyps are not removed. As a result, the disease's increasing incidence is driving the demand for familial adenomatous polyposis therapy.
Market Players Outlook
The major companies serving the global adenomatous polyposis treatment market include Cancer Prevention Pharmaceuticals, Marina Biotech, and Thetis Pharmaceuticals LLC are a few of the market's main companies. To remain competitive in the market, industry players are using different tactics such as mergers and acquisitions, regional expansion, partnerships and collaborations, and new product launches, which contribute considerably to market growth. For instance, Cancer Prevention Pharmaceuticals, Inc. stated in June 2020 that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA). It was hoped that CPP-1X/sul would gain expedited approval for the treatment of adults with familial adenomatous polyposis (FAP).
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global adenomatous polyposis treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Impact of COVID-19 on the Global Familial Adenomatous Polyposis Treatment Market
- Recovery Scenario of Global Familial Adenomatous Polyposis Treatment Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. BY Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Cancer Prevention Pharmaceuticals
3.1.1.1. Overview
3.1.1.2. Financial Analysis
3.1.1.3. SWOT Analysis
3.1.1.4. Recent Developments
3.1.2. Marina Biotech
3.1.2.1. Overview
3.1.2.2. Financial Analysis
3.1.2.3. SWOT Analysis
3.1.2.4. Recent Developments
3.1.3. Thetis Pharmaceuticals LLC
3.1.3.1. Overview
3.1.3.2. Financial Analysis
3.1.3.3. SWOT Analysis
3.1.3.4. Recent Developments
3.1.4. Emtora Biosciences
3.1.4.1. Overview
3.1.4.2. Financial Analysis
3.1.4.3. SWOT Analysis
3.1.4.4. Recent Developments
3.1.5. Cancer Prevention Pharmaceuticals
3.1.5.1. Overview
3.1.5.2. Financial Analysis
3.1.5.3. SWOT Analysis
3.1.5.4. Recent Developments
3.2. Key Strategy Analysis
3.3. Impact of COVID-19 on Key Players
4. Market Segmentation
4.1. Global Familial Adenomatous Polyposis Treatment Market by Type
4.1.1. Icosapent
4.1.2. Eflornithine hydrochloride
4.1.3. Aspirin
4.1.4. CEQ-508
4.1.5. Others
4.2. Global Familial Adenomatous Polyposis Treatment Market by Application
4.2.1. Hospitals
4.2.2. Clinics
4.2.3. Others
5. Regional Analysis
5.1. North America
5.1.1. US
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. Cancer Prevention Pharmaceuticals, Inc.
6.2. Marina Biotech, Inc.
6.3. Thetis Pharmaceuticals LLC
6.4. SLA Pharma
1. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
2. GLOBAL ICOSAPENT FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL EFLORNITHINE HYDROCHLORIDE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL ASPIRIN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
5. GLOBAL CEQ-508 FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6. GLOBAL OTHER FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
7. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
8. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT FOR HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
9. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT FOR CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
10. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT FOR OTHER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
11. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
12. NORTH AMERICAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
13. NORTH AMERICAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
14. NORTH AMERICAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
15. EUROPEAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
16. EUROPEAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
17. EUROPEAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
18. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
19. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
20. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
21. REST OF THE WORLD FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
22. REST OF THE WORLD FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
23. REST OF THE WORLD FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET, 2021-2028 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3. RECOVERY OF GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET, 2022-2028 (%)
4. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SHARE BY TYPE, 2021 VS 2028 (%)
5. GLOBAL ICOSAPENT FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
6. GLOBAL EFLORNITHINE HYDROCHLORIDE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
7. GLOBAL APSIRIN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
8. GLOBAL CEQ-508 FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
9. GLOBAL OTHER FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
10. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SHARE BY APPLICATION, 2021 VS 2028 (%)
11. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT FOR HOSPITALS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
12. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT FOR CLINICS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
13. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT FOR OTHER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
14. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
15. US FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
16. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
17. UK FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
18. FRANCE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
19. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
20. ITALY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
21. SPAIN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
22. REST OF EUROPE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
23. INDIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
24. CHINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
25. JAPAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
26. SOUTH KOREA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
27. REST OF ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
28. REST OF THE WORLD FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
